INFANT BACTERIAL THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.8 SEK | +0.46% |
|
+4.03% | -2.44% |
| Sales 2022 | - | Sales 2023 | 0.08 0.84 6.42 | Capitalization | 1.21B 13.26B 101B |
|---|---|---|---|---|---|
| Net income 2022 | -65M -711M -5.42B | Net income 2023 | -123M -1.35B -10.26B | EV / Sales 2022 | - |
| Net cash position 2022 | 336M 3.67B 28B | Net cash position 2023 | 329M 3.6B 27.44B | EV / Sales 2023 | 11,47,22,57,143 x |
| P/E ratio 2022 |
-8.58
x | P/E ratio 2023 |
-9.04
x | Employees | 8 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.04% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.46% | ||
| 1 week | +4.03% | ||
| Current month | +9.75% | ||
| 1 month | +15.83% | ||
| 3 months | -12.20% | ||
| 6 months | +4.03% | ||
| Current year | -2.44% |
1 week
83.00
89.40
1 month
76.2089.80
Current year
70.80107.00
1 year
41.30107.00
3 years
41.30122.40
5 years
41.30274.50
10 years
32.70274.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 01/13/01 | |
Maria Ekdahl
DFI | Director of Finance/CFO | 51 | 19/22/19 |
| Chief Operating Officer | 57 | 20/14/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margareta Hagman
BRD | Director/Board Member | 58 | 24/15/24 |
| Chairman | 74 | 01/11/01 | |
Anthon Jahreskog
BRD | Director/Board Member | 44 | 04/17/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 87.8 | +0.46% | 252 |
| 25/24/25 | 87.4 | -0.46% | 914 |
| 24/24/24 | 87.8 | +2.09% | 8,502 |
| 23/24/23 | 86 | -1.38% | 1,551 |
| 22/24/22 | 87.2 | +3.32% | 1,142 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:52 pm IST
More quotes
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâs focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -2.44% | 108M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- IBT B Stock
